Evaluating Thrombolytic Therapy in Acute Myocardial Infarction
نویسندگان
چکیده
T he primary goal of thrombolytic therapy in acute myocardial infarction (AMI) is the early restoration of perfusion and maintenance of viability and function of myocardium that would otherwise undergo necrosis consequent to thrombotic coronary artery occlusion. The salvage achieved by thrombolysis ranges from a minute amount of myocardium of little functional significance to a large mass of heart muscle the necrosis of which could cause death, with an intermediate quantity in most patients. The most dramatic outcome of thrombolytic therapy is reduced in-hospital mortality,'-4 but early mortality is a relatively crude end point for measuring variations in the extent to which a given regimen accomplishes the primary goal of thrombolytic therapy defined above. Successful thrombolytic therapy also reduces the frequency of serious complications of AMI such as congestive heart failure and cardiogenic shock.5 Laboratory measurements reflecting benefit include preservation of left ventricular function and the early reestablishment and subsequent maintenance of patency of the infarct-related coronary artery. The favorable outcome of thrombolytic therapy is in some instances offset by recurrent infarction and by adverse effects, e.g., severe bleeding, including the most serious of all complications hemorrhagic stroke. These other (nonfatal) outcomes should also be taken into account in assessing thrombolytic therapy. The favorable effects of thrombolytic therapy have been clearly demonstrated in placebo-controlled trials, and when laboratory measurements such as coronary artery patency or left ventricular function are taken as end points, benefit can be shown in studies comprising only several dozen or a few hundred patients.5-10 To compare the effects of thrombolytic therapy and placebo on survival, however, trials involving several thousands of patients for each are required.1-4 With the exception of special groups of patients, such as those with ST segment depression and those who present relatively late, i.e., more than 6 hours after the onset of symptoms, the benefits of thrombolytic therapy on survival have now been so clearly established that placebocontrolled trials are no longer needed, nor would they
منابع مشابه
Comparison of the Success Rate of Treatment with Primary Percutaneous Coronary Intervention PCI versus Thrombolytic Treatment in Patients with ST-Elevation Myocardial Infarction in Local Hospitals in Iran
Background and Objective: Acute myocardial infarction (MI) is caused due to coronary artery occlusion and divided into two forms of ST-elevation (STEMI) and non-ST-elevation (NSTEMI) myocardial infarction. This study aimed to determine the success rate of treatment with primary PCI (percutaneous coronary intervention) versus thrombolysis in the establishment of perfusion and to evaluate the sho...
متن کاملAn approach to evaluating thrombolytic therapy in acute myocardial infarction. The 'unsatisfactory outcome' end point.
متن کامل
Anti-streptokinase Antibody Detection before and Immediately after Streptokinase Therapy in Patients with Myocardial Infarction
Background: Myocardial infarction (MI) is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. Streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following MI in most countries including Iran. Our previous study showed that, the prevalence of high antibody titers a...
متن کاملComparing the Mean Age of Acute Myocardial Infarction Occurrance in 1989 and 1999
Abstract Acute myocardial infarction (AMI) is the leading cause of death in most countries. With the advent of modern coronary care units CCU during the last decades particularly since 1960, the thrombolytic therapy and interventional techniques including angioplasty; the mortality of AMI has decreased significantly. Moreover the vigilant approach towards diagnosis and control of risk factors ...
متن کاملThrombolytic therapy for acute myocardial infarction.
Numerous factors must be considered when determining the formulary status of thrombolytic agents for the treatment of acute myocardial infarction. Defined treatment options, predicted outcomes, and the economic consequences of this disorder continue to evolve from clinical trials. Pharmacists have a major role in delivering patient care, with responsibility for evaluating, procuring, and monito...
متن کاملمعیارهای جدید برای تشخیص سریع سکته حاد قلبی در حضور بلوک شاخه ای چپ
It is a common Knowledge that the ECG diagnosis of myocardial infarction in the presence of left bundle branch block (LBBB) is extremely difficult and often impossible. Physicians frequenlly recommend that patients with chest pain in the presence of LBBB receive thrombolytic therapy or urgent coronary arteriography assuming that acute injury and ischemia cannot be interpreted in the presence o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2005